Research programme: birch pollen allergy immunotherapy - Immunotek

Drug Profile

Research programme: birch pollen allergy immunotherapy - Immunotek

Alternative Names: Bet-v1 viscogel; Birch pollen viscogel; Viscogel-Bet v 1

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lytix Biopharma
  • Developer Immunotek SL; Lytix Biopharma; Viscogel AB
  • Class Allergens; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Seasonal allergic rhinitis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Seasonal-allergic-rhinitis in European Union (Sublingual, Gel)
  • 10 Sep 2013 Early research in Seasonal allergic rhinitis in European Union (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top